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Prion Amplification and Hierarchical
Bayesian Modeling Refine Detection of
Prion Infection
A. Christy Wyckoff1,2*, Nathan Galloway3*, Crystal Meyerett-Reid1, Jenny Powers4, Terry Spraker1,
Ryan J. Monello4, Bruce Pulford1, Margaret Wild4, Michael Antolin3, Kurt VerCauteren2 & Mark Zabel1
1Colorado State University Prion Research Center, Department of Microbiology, Immunology and Pathology, College of Veterinary
Medicine and Biomedical Sciences, Fort Collins, CO 80523, USA, 2National Wildlife Research Center, Wildlife Services, United
States Department of Agriculture, La Porte Avenue, Fort Collins, CO 80521, 3Department of Biology, College of Natural Sciences,
Colorado State University, Fort Collins, Co 80523, 4National Park Service, Biological Resource Management Division, 1201
Oakridge Drive, Fort Collins, CO 80525, USA.
Prions are unique infectious agents that replicate without a genome and cause neurodegenerative diseases
that include chronic wasting disease (CWD) of cervids. Immunohistochemistry (IHC) is currently
considered the gold standard for diagnosis of a prion infection butmay be insensitive to early or sub-clinical
CWD that are important to understanding CWD transmission and ecology. We assessed the potential of
serial protein misfolding cyclic amplification (sPMCA) to improve detection of CWD prior to the onset of
clinical signs. We analyzed tissue samples from free-ranging Rocky Mountain elk (Cervus elaphus nelsoni)
and used hierarchical Bayesian analysis to estimate the specificity and sensitivity of IHC and sPMCA
conditional on simultaneously estimated disease states. Sensitivity estimates were higher for sPMCA
(99.51%, credible interval (CI) 97.15–100%) than IHC of obex (brain stem, 76.56%, CI 57.00–91.46%) or
retropharyngeal lymph node (90.06%, CI 74.13–98.70%) tissues, or both (98.99%, CI 90.01–100%). Our
hierarchical Bayesian model predicts the prevalence of prion infection in this elk population to be 18.90%
(CI 15.50–32.72%), compared to previous estimates of 12.90%. Our data reveal a previously unidentified
sub-clinical prion-positive portion of the elk population that could represent silent carriers capable of
significantly impacting CWD ecology.
C
WD is a neurodegenerative disease first seen in captive Colorado cervid populations in 1967, later
identified as a transmissible spongiform encephalopathy (TSE) in 19781 and first found in free-ranging
populations in 19811,2. Prions, the infectious agent of TSEs, arise from the misfolding of the normal host-
encoded cellular prion protein (PrPC) into an insoluble, aggregated and infectious form that resists protease
degradation. Prions causing CWD arise from PrPCWD, the misfolded, infectious form of cervid PrPC. CWD, the
only known TSE to occur in free-ranging wildlife, affects several cervid species including elk (Cervus elaphus
nelsoni), mule deer (Odocoileus hemionus), white-tailed deer (O. virginianus) and less commonly moose (Alces
alces spp.). Prevalence of CWD in free-ranging deer populations in Colorado and Wyoming ranges from 0–30%
and prevalence in free-ranging elk herds ranges from 0–13% in Colorado3–6. CWD and sheep scrapie are capable
of both horizontal transmission from infected individuals7–9 as well as efficient indirect transmission from
contaminated environments10–13.
Despite cross-species transmissibility of PrPCWD among cervids, the pathogenesis of the disease may be
different between deer and elk. For example, studies with experimentally infected deer suggest that PrPCWD infect
and replicate in peripheral lymphatic tissues prior to neuroinvasion14,15. Studies with captive or experimentally
infected elk are less conclusive and suggest prions may first be detectable in the obex of the brain stem or the
retropharyngeal lymph node without a clear pattern16–18. Studies of free-ranging elk, however, suggest that
PrPCWD can likely be detected first in lymphatic tissue19. It is unclear if route of inoculation or prion strain can
also affect these apparent differences.
Infected animals shed prions into the environment through saliva, feces, urine and even antler velvet15,20–24.
Studies have successfully transmitted PrPCWD through a single dose of urine or feces from animals displaying signs
of CWD, indicating that at the time of clinical disease sufficient prions are shed to result in an infectious dose24,25.
However, at what stage(s) of disease animals shed prions into the environment remains unclear. If shedding
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occurs early in disease, a sub-clinical animal may not only shed
prions into the environment, increasing the infectious reservoir,
but may also transmit CWD horizontally to their associates.
Unfortunately little is known about the prevalence of early or sub-
clinical infection, and what role they may play in CWD transmission
ecology. This ignorance raises a critical question that must be
answered: how long do free-ranging animals live once infected?
Answering it requires detection of prion infections as early as pos-
sible in the course of infection.
Cervid prion protein gene (PRNP) polymorphisms can influence
CWD kinetics. Elk PRNP methionine or leucine polymorphism at
codon 132 can dramatically affect incubation time and possibly sus-
ceptibility of inoculated elk20–24,26. Experimental and observational
evidence suggests that 132LL homozygous elk are rare (#2.5%) in
free-ranging populations20,25,27,28, and when inoculated have a sub-
stantially delayed disease course (.48 months) in captivity com-
pared to MM homozygote and ML heterozygote elk (12–24
months)26,29. Despite differences in disease kinetics, Perucchini
et al.27 found that the prevalence of CWD within elk genotypes was
not disproportionate, indicating the three genotypes maintain pro-
portional CWD prevalence despite the disease course differences.
Whether cervid PRNP genotype affects transmission and shedding
of PrPCWD remains uncertain. Surveys of free-ranging deer suggest
increased rates of CWD between 2–11 years of age30 but work on elk
suggests a much wider age range can be infected19 and no study to
date has quantified the interaction between age and prevalence of
CWD in elk.
Currently, prion protein immunohistochemistry (IHC) of brain
tissue and lymph nodes is the gold standard for CWD detection31.
However, this method requires 2–3 weeks for sample preparation,
relatively large quantities of well-preserved tissue and specialized
training for accurate microscopy work. Commercially available
enzyme-linked immunosorbent assay-based tests detect prion infec-
tionmore rapidly, andwith similar sensitivity to IHC32. Serial protein
misfolding cyclic amplification (sPMCA) has emerged in the field of
prion research as a reliable and sensitive alternative detection assay
for a variety of tissue and sample types1,22,27,33–37. Haley et al.38 found
comparable sensitivity between an abbreviated sPMCA vs. IHC in
longitudinal tonsil biopsies from experimentally inoculated, captive
white-tailed deer.
We have optimized both sensitivity and specificity to maximize
PrPCWD amplification and detection, leading to a more sensitive
sPMCA protocol that processes samples in less than two weeks23.
We used sPMCA to test obex tissue samples from a free-ranging elk
herd in the RockyMountain National Park (RMNP), Estes Park, CO;
and Bayesian hierarchical modeling to compare our results to IHC of
retropharyngeal lymph node and obex tissue and estimate prevalence
of PrPCWD in this herd.
Results
Of the 85 elk tested, 20 were IHC-positive in one or more tissues
(Table 1). Of the 20 IHC-positive animals, sPMCA identified 19
correlating obex samples as positive. The one sample that sPMCA
did not generate a positive result for was a 2011 sample found to be
IHC-positive in the RPLN only. sPMCA also identified an additional
18 IHC-negative samples as PrPCWD-positive.
We found a strong correlation between sPMCA and IHC scores
for each elk sample (Figure 1). Linear regression found a positive
association (slope 5 0.39, R2 5 0.64) between samples scoring pos-
itive by both IHC and sPMCA. Samples that disagreed, scoring IHC
negative but sPMCA positive, were not included in the linear regres-
sion, but are overlaid in Figure 1 to show the low sPMCA scores of
samples that were otherwise IHC-negative. A high rate of sPMCA-
positive samples in 2010 suggested an unidentified portion of those
samples may have been false-positives due to contamination. This
may also be the case for 2009. However, sPMCA did identify 4
additional positives in 2011 compared to the 3 found by IHC (6 total,
Table 1 and Figure S1). One of the IHC-positive samples was the
single disagreement mentioned above.
We developed a novel hierarchical Bayesian model to estimate
specificity, sensitivity and disease prevalence that considers all IHC
and sPMCA test results (Figure 2). The model simultaneously esti-
mates infection status of each individual animal and all derived
quantities of interest, including estimates of PrPCWD prevalence
within the herd, and sensitivity and specificity of IHC for each tissue
and sPMCA. This model also allowed us to quantify the potential
effects of contamination in two of the collection years (2009 and
2010).
The separate analysis of Trusted and Unknown samples allowed
us to estimate sPMCA specificity by amplification round (Figure 3a)
and for each group of samples (Figure 3b). When compared to spe-
cificity of raw data from previous sPMCA studies23,35,39 (99.60%, CI
98.00–100%) ourmodel estimates specificity for our Trusted samples
to be 93.85% (CI 90.00–96.84%), and a reduced specificity of 61.98%
(CI 51.81–71.18%) for Unknown samples after six PMCA rounds.
We did not separate samples into Trusted and Unknown groups
for sensitivity analyses because sensitivity is the ability of the test to
correctly identify a true positive. The sensitivity of sPMCA after 6
rounds was estimated at 94.68% (CI 83.12–99.84%) for one replicate.
Again we compared sensitivity of known positive samples (97.00%,
confidence interval 95.07–99.02%) from previous work to dem-
onstrate the agreement between raw data and the model estimates
(Figure 3C). We typically assess at least two replicate samples by
PMCA, which our model predicts to increase sensitivity to 99.51%
(CI 97.15–100%) with corresponding decreases in specificity of
trusted (91.03%, CI 84.42–97.80%) and unknown (42.01%, CI
27.72–50.11%) samples.
We also calculated sensitivity estimates for IHC of obex and RPLN
(Figure 3D). RPLN IHC (90.06%, CI 74.13–98.70%) was more sens-
itive than obex (76.56%, CI 57.00–91.46%). Combining obex and
RPLN IHC increases sensitivity to 98.99% (CI 90.01–100%).
Inputting all data from the two IHC and duplicate PMCA tests,
our model estimated the overall period prevalence of CWD for
2009–2011 to be 18.90% (CI 8.71–32.39%; Figure 4).
The age distribution of elk sampled by year showed an overlap
among years, with 2009 and 2010 including primarily middle-aged
animals (Figure 5A). Our model predicts the primary age of infected
animals lies between 2–11 years (Figure 5B). Means and credible
intervals for the logistic regression coefficients, H, are reported in
Supplemental Table 2. No difference in overall prevalence was found
between MM and ML elk (p 5 1.0).
Discussion
We compared specificity and sensitivity estimates of two tests for
CWD prions in a free-ranging elk herd in RMNP, the gold standard
PrPCWD IHC versus sPMCA testing analyzed by Bayesian hierarch-
ical modeling.We found that sPMCA detected PrPCWD in the obex of
infected elk with greater sensitivity than IHC of obex or RPLN. We
used these estimates to predict prevalence of prion infection in this
herd, and discovered animals with subclinical CWDmay represent a
significant carrier state in this population. Although there appears to
be no upper age limit to infection in adult female elk19, we found that
prevalence decreases with age and the primary age cohort for infec-
tion is 2 to 11 years.
sPMCA specificity was lower than expected, likely due to cross-
contamination during necropsy in early years, which was reflected in
the difference in sPMCA-positive results between 2010 and 2011.
Our decontamination protocol instituted during necropsy in 2011
to limit cross-contamination reduced the sPMCA-positive rate to
twice the IHC rate (sPMCA 5 18.2% and IHC 5 9.1%, Table 1).
Our cross-contaminationmitigation strategy provided us with a year
of samples that we considered contamination-free.
www.nature.com/scientificreports
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We therefore consider the data showing the identification of 4
additional positive samples by sPMCA in 2011 to be reliable, and
used them to inform our model of sPMCA specificity and sensitivity
compared to IHC. Detection of four unique positives by sPMCA
correlates with the low amounts of PrPCWD predicted to exist in
animals with early and sub-clinical disease.
Hierarchical Bayesianmodeling allowed us to work with authentic
but possibly imperfect data and let the model test parameters to find
the best estimates. Having to discount some of the sPMCA findings
for 2009 and 2010 was not ideal, but the model allowed us to adapt to
the realities of research. When we removed possible false-positive
results for specificity estimates the model estimated that specificity
increased from 61.98% (Unknown samples) to 93.9% (Trusted sam-
ples). Uncertainty introduced by possible sample contamination
likely resulted in the model predicting a lower specificity in these
field samples than our previous specificity of 99.6% observed in
controlled laboratory experiments35. Increased specificity using
Trusted while excluding Unknown samples shows that sPMCA has
a high specificity when cross-contamination is prevented. Moreover,
if replicate samples are used, sensitivity increases to 99. 51%, while
specificity remains acceptable at 91.03%. We consider these to be
conservative estimates of sensitivity and specificity considering pos-
sible contamination at early collections, and our model allows us to
use imperfect data to inform our model and estimate prevalence in
this herd.
Our results suggest that prevalence of prion infection in this free-
ranging RMNP elk herd is much higher than previously reported.
Prior to 2013, the CWD prevalence in elk surrounding RMNP was
estimated at ,2%19,40,41. In 2013, Monello et al. reported CWD pre-
valence of 12.9% in RMNP based on PrPCWD IHC of RAMALT19,35,
over 4 times higher than previous reports. Here we report an esti-
mated overall prevalence of 18.90%, consistent with the finding by
Monello et al., who found 28% of adult female elk were infected
during the course of their three-year study. We conclude that
sPMCA can detect early cases of PrPCWD infection and our model
conservatively estimated overall prevalence since all known PrPCWD
positive animals from 2008, which tested positive on RAMALT
biopsy, were removed from the sample population.
The higher overall prevalence estimate in this herd suggests pre-
vious measurements have been missing a large portion of PrPCWD -
positive animals and that a long history of exposure to prions and
decades of relatively high densities on the winter range may have led
Table 1 | Summary of detection assay results
Sampling Year n 5 elk sampled sPMCA 1
IHC 1
Obex RPLN Ob & RPa IHC 1 Total
2008b 11 11 11 11
2009 17 5 c 1 1
2010 24 17c 1 3 1 5
2011d 33 6e 1 2 3
Totals 85 39 1 4 15 20
aPrPCWD was found in both obex and RPLN samples.
ball animals were RAMALT-positive at start of study, euthanized in the field within two months and tested further.
cCross-contamination of tissue samples at necropsy likely resulted in some false sPMCA-positives these years.
dA decontamination protocol was put in place to prevent cross-contamination at necropsy.
esPMCA identified 4 additional samples that were positive for PrPCWD, but misdiagnosed one that was positive via IHC in RPLN only (the only such misdiagnosis by sPMCA).
Figure 1 | Correlation between IHC score and sPMCA score of each sample. (a) Sample scores by IHC and sPMCA were compared by linear regression
to evaluate correlation between the two tests. Samples found positive by both tests are considered in ‘‘Agreement’’ (black circles). Samples found negative
by IHC but positive by sPMCA are considered in ‘‘Disagreement (grey triangles). Each data point represents the mean of all replicates per animal.
(b) Representative IHC of a positive obex sample. Scale bars, 100 mm. (c) Representative western blots: Lane 1, undigested NBH; lanes 2–3, negative elk
obex from ND and MT after 6 rounds of sPMCA. Lanes 4–5, RMNP elk obex featured in (b) after 3 and after 6 sPMCA rounds (lanes 6 & 7).
www.nature.com/scientificreports
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Figure 2 | Model network diagram. Network diagram outlining the hierarchical Bayesian model used to estimate specificity and sensitivity of IHC and
sPMCA and population prevalence of CWD. Ob, Obex; RP, Retropharyngeal lymph node; Unk, Unknown samples; Tr, Trusted samples.
Figure 3 | Specificity and sensitivity estimates of sPMCA and IHC. (a) Specificity estimates of sPMCA by amplification round. Three sample groups are
presented: Known samples are positive controls used in previous studies and presented as raw data; Trusted samples are those which are verified by IHC or
are from the 2011 sampling; and Unknown samples are all remaining samples which may include contamination-related false positives. (b) Overall
sPMCA specificity estimates for Trusted and Unknown samples. The overall specificity of sPMCA is estimated at 93.9% (CI 90.1–96.9%) for Trusted
samples and 63.4% (CI 52.6–74.1%) for Unknown samples. (c) Sensitivity of sPMCA by round. Sensitivity increases with each amplification round to
94.68% (CI 83.12–99.84%) by round 6. (d) Overall sensitivity estimates for IHC and sPMCA. Sensitivity estimates for IHC by individual tissue (obex
(76.56%, CI 57.00–91.46%) and RPLN (90.06%, CI 74.13–98.70%)) and combined 98.99% (CI 90.01–100%); one replicate of sPMCA after 6 rounds
(94.68%, CI 83.12–99.84%); and two replicates of sPMCA (99.51%, CI 97.15–100%).
www.nature.com/scientificreports
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to increased prevalence19,42,43. Further study is required to identify
possible ecological differences in this herd compared to neighboring
ones.
As an amplifying assay, sPMCA has previously been shown to be
extremely specific and sensitive in prion detection studies19,22,40,44,45
but had not been directly compared to IHC in elk or in samples from
free-ranging animals. This study has shown that sPMCA on the obex
alone is more sensitive than IHC on obex or RPLN. sPMCA also
detected several positive obex samples, which were IHC-negative
from 2011. We argue that this increased detection represents early
stage infections or sub-clinical animals, which may or may not shed
PrPCWD or develop clinical disease at a later time point.
Similar to Monello et al.19, our sensitivity analysis of IHC by tissue
indicates that in this study population, that IHC in the RPLN was
actually more effective in detecting positives animals than the obex.
These results indicate that IHC on the obex might not be the best
method to detect nascent PrPCWD in elk, and perhaps the premise that
the infection course is different between deer and elk is not absolute.
Determining whether sPMCA in the RPLN would show a similar
improvement on sensitivity compared to obex requires further study.
Our data demonstrate that previous IHC-based studies are pos-
siblymissing early stage or sub-clinical cases in sampled populations.
It is widely accepted that IHC is sensitive enough to detect pre-
clinical cases, but we propose that sPMCA can detect additional cases
even earlier, possibly soon after infection. In previous work we found
sPMCA had a detection limit of 1029 35,46 which is much more sens-
itive than the sensitivity of a mouse bioassay at 1024. This suggests
that animals found positive by sPMCA have much lower levels of
PrPCWD than animals with clinical disease, but are indeed infected.
The detection of very early sub-clinical cases raises the question of
biological relevance at the population level.We propose that this sub-
clinical subset of the populationmay be ecologically important to the
disease transmission cycle because of potential preclinical vertical
transmission from mother to offspring47, horizontal transmission
through direct contact, or indirect transmission through envir-
onmental deposits of prions.
It remains unclear when animals begin shedding prions into the
environment. Through the use of a mouse bioassay Tamguney
et al.22,24,44,45 showed asymptomatic deer were capable of shedding
infectious levels of CWD as early as 10 months prior to clinical
disease. Bioassays, both in mice and deer, have limited sensitivity
so shedding could be occurring much earlier than 10 months post-
infection but at levels insufficient to cause clinical disease in the
infected host. It is also unclear if genotype plays a role in prion
shedding, as well as disease course. Our data suggest that having at
least one L allele at codon 132 does not alter the disease prevalence
within the ML genotype, supporting data reported by Perucchini
et al.27. The slow disease course and the potential existence of a carrier
state facilitate a high prevalence and frequent opportunity for trans-
mission between animals with the MM and ML genotypes.
It is commonly stated in the literature that CWD is an invari-
ably fatal disease, but it may be more accurate to state that once
animals begin to show clinical signs they are certain to succumb to
CWD or other associated causes of death such as predation4,24,48.
Perhaps other carrier states exist within the population, which
may or may not contribute to the transmission and deposition
of prions in the population and the environment. Further research
is required to address the role of a carrier state in the ecology of
CWD transmission.
Figure 4 | Overall prevalence estimate of prion infection for elk sampled
in 2009-2011. The gray shaded area under the curve represents the 95%
confidence interval.
Figure 5 | Age effect on prion infection prevalence. (a) Age distribution of
animals sampled by year. (b) Derived posterior probability density for
prevalence (P(z 5 1)) across observed ages. Black dots represent mean
values and gray dots, 95% confidence intervals. Left y-axis shows
prevalence within age groups demonstrating the predominant age of
infected animals lies between 2 and 10 years as previously documented.
The right y-axis and the histogram in the background show the observed
frequency of ages of elk sampled in this study.
www.nature.com/scientificreports
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The application of sPMCA will be important both to research and
for diagnostic investigation, and may improve state and federal sur-
veillance programs for CWD in both naı¨ve and endemic host popu-
lations. Increased sensitivity, and the need for only obex tissue, may
lead to detection of new focal points prior to clinical disease emerging
in otherwise CWD-free populations. Additionally, in the econom-
ically and politically difficult scenario of culling captive herds that
tested positive for CWD, extremely sensitive assays such as sPMCA
of prions from tissue and excreta are essential to verify that more
animals besides the index case were infected, and if any sub-clinical
carriers may have been shedding into the environment.
Overall, our data contribute to the increasing evidence that a por-
tion of a herd may be infected, but die from other causes while
infected with PrPCWD because of age, genetic susceptibility or other
unknown factors. However, the contribution of prions shed into the
environment from this sub-clinical population may be important
and requires further investigation. The existence of an infectious
PrPCWD carrier state aligns with disease ecology theory, which pro-
poses balance between transmissibility and pathogenesis of a patho-
gen. As such, through selection pressures from the host and external
environment the pathogen will tend towards the greatest transmis-
sibility strategy. CWD transmission may be more complicated than
disease ecologymight predict, since prolonged persistence and indir-
ect transmission of prions in the environment may potentiate spread
without affecting pathogenesis.
Despite the fact that prions are only protein, studies continue to
point at evolutionary behavior and selection pressures of prions
which indicate that like other pathogens, prions are capable of evol-
ving and adapting to their environment4,27,48,49. With increasing pre-
valence at the population level, as is reported in this study, sPMCA
will continue to be an important tool to investigate CWD in wildlife.
Methods
Mice.All mice were bred and maintained at Lab Animal Resources, accredited by the
Association for Assessment and Accreditation of Lab Animal Care International, in
accordance with protocols approved by the Institutional Animal Care and Use
Committee at Colorado State University.
Elk brain tissue samples. Brain tissues were collected at necropsy from 85 free-
ranging elk that were radio collared and later euthanized for research and
management purposes19. Briefly, 136 elk were initially captured, sampled and collared
in 2008. Rectoanal mucosal-associated lymphatic tissue (RAMALT) samples were
collected from each elk during initial capture and tested for PrPCWD by IHC7–9,38,50. In
2008, samples were collected from 11 PrPCWD -positive animals that were recaptured,
euthanized and necropsied within two months of original capture. In subsequent
years 17, 24, and 33 randomly selected animals were recaptured, euthanized,
necropsied, and included in this study. These opportunistic collections were IHC-
negative via RAMALT biopsy in 2008 and no elk exhibited clinical evidence of CWD
when euthanized. Elk were euthanized in the field then transported to the TSE
necropsy facility at the Colorado State University Veterinary Teaching Hospital
within 8 hours of euthanasia19. We removed a primary incisor from all elk carcasses
to determine age by cementum analysis (Matson Lab, Milltown, MT). Field
euthanasia and subsequent necropsies were approved by NPS (permit ROMO-2007-
SCI-0077), ColoradoDivision ofWildlife (permit TR1081), and CSU IACUC (permit
07-231A).
Multiple tissues were collected from each animal during necropsy. Here we com-
pare IHC results from obex and retropharyngeal lymph nodes14,15,50,51 to sPMCA
results from the obex alone. All lymph node samples and half the obex sample were
fixed in 10% neutral buffered formalin for IHC analaysis; the other half of the obex
sample was stored in a whirl pack at 280uC for testing by sPMCA.
IHC. Sections of retropharyngeal lymph node (RPLN) and obex were examined by
IHC as previously described16,50. Briefly for IHC, tissues were fixed, paraffin-
embedded and 10 mm sections cut, mounted on glass microscope slides, and
immunolabeled with anti-prion protein monoclonal antibodies (mAbs) F99/97.6.1
(mAb 99) and mAb P4. PrPCWD was visualized by incubation with alkaline
phosphatase (AP)-conjugated donkey antibodies against mouse IgG and fast red
chromogen that revealed red aggregate deposits in neural and lymphoid tissues. A
scoring system (0–10) was used to evaluate intensity of PrPCWD deposition as
described in Spraker et al.52.
Brain Homogenization. Frozen elk obex samples were partially thawed and
approximately 200 mg of tissue was collected from the interior of the obex sample,
placed into a 2 ml tube containing silica beads and 180 ml of sPMCA buffer #1
(150 mMNaCl, 4 mMEDTA, in PBS) was added. Tissues were homogenized using a
FastPrep machine (Thermo Scientific) as outlined in Meyerett et al.46. The clarified
10% homogenate supernatant was removed and stored at 280uC.
sPMCA substrate consisted of 10% mouse normal brain homogenate (NBH)
prepared in a prion-free room fromTg5037mice expressing cervid PrPC as previously
described46.
sPMCA and western blotting. Twenty-five ml of RMNP elk obex homogenate was
added to 25 ml NBH in 0.2 ml tubes. Samples were sonicated in a Misonix 4000
sonicator (Misonix Inc., Farmingdale, NY) for 40 s every 30 minutes for 24 hours at
37uC constituting one round46. For each subsequent round, 25 ml of each sample from
the previous round was combined with 25 ml of fresh NBH. Duplicate samples were
run for 6 sPMCA rounds to balance desired sensitivity and specificity (.90%) as
previously observed35. Each sPMCA experiment contained at least six NBH-negative
controls and two positive plate controls (CWD-positive elk brain homogenate E2,
151000). The negative brain samples were collected fromMontana (n5 1) andNorth
Dakota (n 5 10) and homogenized as previously described23 Montana eNBH was
confirmed negative by bioassay in CWD susceptible mice (data not shown) and ND
samples were confirmed negative by ELISA (Bio-Rad Laboratories). Elk samples
collected in 2008 and 2009 were not blind to laboratory researchers, but all 2010 and
2011 samples were blinded. The PrPCWD status of all negative controls was known at
the time of sPMCA.
PMCA samples were assayed by western blot as previously described23,46. Briefly,
18 ml of sample was digested with 2 ml of 50 mg/ml proteinase K (PK, Roche, Basel,
Switzerland) for 30 minutes at 45uC. Samples were electrophoresed, electro-trans-
ferred to PVDF membranes and visualized with HRP-conjugated anti-PrP Bar-224
monoclonal antibody (SPI-Bio, Montigny-le-Bretonneux, France). Because prion
load inversely correlates with the round in which it is first detected, samples were
given a score inversely proportional to the first positive sPMCA round23. For example,
if a sample scored positive in the first of six rounds, it received a sample score of 6. A
positive sample detected in round six would receive a score of 1 and a negative sample
would be scored 0.
Cross-contamination management. During the first three years of necropsies
(2008–2010), decontamination was not standard practice during tissue collection.
Necropsies from 2009–2011 were performed in a new TSE necropsy room, reducing
the risk of contamination. In 2011, a decontamination protocol was implemented to
further prevent cross-contamination during sample collection, including sodium
dodecyl sulfate/acetic acid46,53 treatment of working surfaces and all necropsy
instruments, and glove and apron changes between animals. Disposable sterile
scalpels were used for all CNS tissue harvest. Samples were processed according to
protocols implemented to prevent cross-contamination at the lab bench, including
using sterile scalpels, forceps and clean gloves during sub-sampling, homogenization
and sPMCA.
Model to estimate specificity, sensitivity and prevalence. The model is represented
as a network diagram in Figure 2. Each animal was considered to have a true infection
status, denoted zi, where zi5 0 when animal i is uninfected and zi5 1 when infected.
Infection status was modeled as a logistic regression with age and age covariates2, as
well as a categorical covariate for the samples from the year 2008, such that:
zi*Binom pið Þ
logit pið Þ~b0zb1ageizb2age2izb3yr:08i
b*Norm 0,1:5ð Þ
ð1Þ
For example, the IHC results for the obex tissue were described by amixture model as
follows:
yobex,i*
Binom 1{SpecIHCð Þ, zi~0
Binom SensObexð Þ, zi~1
( )
SensIHC*Beta 1,1ð Þ
ð2Þ
We denote sPMCA results for individual i and replicate j across amplification rounds
t 5 156 as wi,j,t which is contingent upon the latent disease state of individual i,
Sensitivity and Specificity probabilities across amplification rounds, Se and Sp, and
the result from the previous round where applicable, wi,j,t-1.
wi,j,1*
Binom 1{Sp1ð Þ, zi~0
Binom Se1ð Þ, zi~1
 
ð3Þ
wi,j,t
*Binom 1{Sptð Þ, zi~0
*Binom Setð Þ, zi~1
 
, wi,j,t{1~0
~1, wi,j,t{1~1
8<
:
9=
; ð4Þ
Se and Sp represent the probability of a sPMCA test result transitioning from a
negative test result to a positive within amplification round t. These parameters are
modeled as flat Dirichlet distributions of length T1 1. Incorporating the probability
of a negative test result allows the probabilities to sum to one. This transition model is
a modification of the Cormack-Jolly-Seber survival model with perfect detection54.
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The parallel occurs because after a sample is positive in one sPMCA cycle, it remains
positive in the following rounds, just as, for example, a mortality event at any time
guarantees all following times maintain that state. The model was fit to the data in
JAGS 3.1.055,56 with the rjags package55 in the R 2.15.1 computing environment57.
Errors in specificity, or false positives, can occur as a result of cross-contamination
of samples during necropsy or possibly by spontaneous misfolding during sPMCA.
We previously reported our method of sPMCA has a specificity of 99.6% in the
laboratory setting35. Negative samples used for this sPMCA experiment were used to
show specificity in our laboratory setting, but do not account for possible necropsy
contamination of the elk tissues. To remove bias from possible necropsy-related false
positives in years 2009 and 2010 we separated ‘‘Trusted’’ from ‘‘Unknown’’ samples.
Trusted samples were those found positive by IHC (2008–2010) and all samples from
2011, when we employed decontamination techniques at necropsy. Unknown sam-
ples are IHC-negative samples from 2009 and 2010. sPMCA results for these samples
could be true, sub-clinical positives outside of the detection limit of IHC, or they could
be false positives resulting from contamination during sample collection at necropsy.
To maintain a conservative estimate of the specificity of sPMCA, Trusted and
Unknown samples were assumed to have independent specificity probabilities.
Errors in sensitivity, or false negatives, for either assay occurred for two reasons:
either the concentration of PrPCWD was below the detection limit of the assay or,
despite the overall presence of PrPCWD in the tissue, the exacted portion that was
assayed did not contain detectable levels of PrPCWD due to non-homogenous distri-
bution19,30,41,58. All estimates are reported with a 95% Bayesian credible interval (CI).
Genetic data for 30 MM and 30 ML randomly selected animals were used to assess
for prevalence differences between genotypes. IHC and sPMCA results were pooled
allowing for positive or negative status to be tested against MM and ML genotype
status using a Fisher’s Exact Test (p , 0.05).
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